Treatment of patients with severe sepsis using Ulinastatin and Thymosin α1: A prospective, randomized, controlled pilot study

Chinese Medical Journal

Volumn 122, Issue 8, 2009, Pages 883-888

  Chen, Hao ^a   He, Ming Yan ^b   Li, Yu Min ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

Immunomodulatory therapy; Severe sepsis; Thymosina1; Ulinastatin

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; PLACEBO; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ADULT; AGED; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CD4 CD8 RATIO; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLASGOW COMA SCALE; HUMAN; IMMUNOMODULATION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; SEPSIS; SURVIVAL ANALYSIS; THYMOSIN; TREATMENT OUTCOME; TRYPSIN INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68249138156     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.08.001     Document Type: Article

References (40)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SSCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
2. Balk RA. Severe sepsis and septic shock. Crit Care Clin 2000; 16: 179-192.
3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
4. Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep 2003; 52: 1-85.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Carcillo J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated cost of care. Crit Care Med 2001; 29: 1303-1310.
6. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997; 66: 95-101.
7. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol 2003; 24: 254-258.
8. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
9. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-1439.
10. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23: 1294-1439.
11. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study. Crit Care Med 1993; 21: 318-327.
12. Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23: 1461-1469.
13. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with the sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934-941.
14. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351: 929-933.
15. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-1440.
16. Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, et al. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis: a randomized, clinical trial. Crit Care Med 1998; 26: 1650-1659.
17. Reinhart K, Wiegand Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742.
18. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-1702.
19. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis:a phase III, randomized, double-blind, placebo-controlled, multicenter trial.The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-1124.
20. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-1843.
21. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12-21.
22. Astiz ME, Rackow EC. Septic shock. Lancet 1998; 351: 1501-1505.
23. Jonsson BM, Ohlsson K, Rosengren M. Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. BiolChem 1989; 370: 1157-1161.
24. Goldstein AL, Guha A, Zatz MM, Hardy MA, White A. Purification and biological activity of thymosin,a hormone of the thymus gland. Proc Natl Acad Sci USA 1972; 69: 1800-1803.
25. Osvaldt AB, Viero P, Borges da Costa MS, Wendt LR, Bersch VP, Rohde L. Evaluation of Ranson, Glasgow, APACHE-II, and APACHE-O criteria to predict severity in acute biliary pancreatitis. Int Surg 2001; 86: 158-161.
26. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score are reliable descriptor of a complex outcome. Crit Care Med 1995; 23: 1638-1652.
27. Hadak AM, Caesar RR, Frol AB, Krueger K, Harper CR, Temkin NR. Functional outcome scales in traumatic brain injury: a comparison of the Glasgow Outcome Scale (Extended) and the Functional Status Examination. J Neurotrauma 2005; 22: 1319-1326.
28. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematicreview and meta-analysis. BMJ 2004; 329: 480.
29. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The Effects of Ibuprofen on the Physiology and Survival of Patients with Sepsis.The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912-918.
30. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-436.
31. Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ. Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gramnegative infections. Prog Clin Biol Res 1991; 367: 179-186.
32. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003; 2: 391-405.
33. Nishiyama1 T, Yokoyama T, Yamashita K. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery. J Anesth 2006; 20: 179-182.
34. + cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol 1999; 21: 15-26.
35. The Cooperative Group of Immunomodulatory Therapy of Sepsis, Lin HY. Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin. Natl Med J China (Chin) 2007; 87: 451-457.
36. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor-α production of monocytes. Shock 2001; 15: 101-105.
37. Sato Y, Ishikawa S, Otaki A, Takahashi T, Hasegawa Y, Suzuki M, et al. Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury. Jpn J Thorac Cardiovasc Surg 2000; 48: 428-434.
38. Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs 2002; 3: 698-707.
39. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004; 103: 4232-4239.
40. Witthaut R, Werdan K, Schuster HP. Multiple organ dysfunction syndrome and multiple organ failure. Diagnosis, prognosis and therapeutic concepts. Internist (Berl) 1998; 39: 493-501.